Trial Profile
A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Sep 2022
Price :
$35
*
At a glance
- Drugs Donaperminogene seltoplasmid (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- Acronyms REViVALS-1A
- Sponsors Helixmith
- 23 Sep 2022 Status changed from active, no longer recruiting to completed.
- 22 Sep 2022 Topline results published in the Helixmith Media Release.
- 06 Sep 2022 According to a Helixmith media release, the company will continue the analysis of the data upon the receipt of the full report and plan to present results at a future conference and determine next steps for Engensis in ALS at that time.